HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
“Multiple components of the HIF1 signalling pathway have been identified as candidate drug target”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
BackgroundExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
“Targeting HIF-1 The characteristics, functions and possibilities for targeting HIF-1 in cancer therapy have been recently reviewe”
BackgroundHypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
“HIF1 inhibitors with metabolic effects Investigators are also attempting to inhibit the HIF1 transcription factor in an effort to block the metabolic effects as well as other physiological pathways that are regulated by HIF1 in the solid tumour (such as angiogenesis”
BackgroundHypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“HIF-1α is an oxygen-unstable protein that becomes stable in response to hypoxia, iron chelators, and divalent cations.(81,82) In cell culture under hypoxic conditions, HIF-1α mRNA levels did not change, but HIF-1α protein levels increased.”
Background
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIF-1 as a target for drug development. https://app.cochat.ai/papers/10.1038/nrd1199
- The paper
- Giaccia, A., Siim, B. G., & Johnson, R. S. (2003). HIF-1 as a target for drug development. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1199
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.